Elicio Therapeutics, Inc.
ELTXElicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies designed to treat various forms of cancer, including pancreatic, colorectal, and lung cancers.
Earnings
Next report
Date not yet announcedCompetitors
By market cap
By revenue growth
Profile
Elicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies designed to treat various forms of cancer, including pancreatic, colorectal, and lung cancers. The company utilizes its proprietary Amphiphile (AMP) technology to deliver therapeutic payloads directly to the lymph nodes, aiming to activate a robust T cell response. Their core value proposition lies in creating "off-the-shelf" immunotherapies that target common tumor mutations, potentially offering a more accessible and cost-effective alternative to personalized cancer treatments.
Elicio is a clinical-stage innovator leveraging a niche lymph-node targeting technology to improve the efficacy of off-the-shelf cancer vaccines.
FAQ
- What is Elicio Therapeutics, Inc.'s market cap?
- Elicio Therapeutics, Inc. (ELTX) has a market capitalization of $82.5M and trades on NASDAQ.
- Who are Elicio Therapeutics, Inc.'s competitors?
- Elicio Therapeutics, Inc.'s key competitors include Moderna, Inc., Amgen Inc., AIM ImmunoTech Inc., and others. These companies compete in similar markets and product categories.
- Where is Elicio Therapeutics, Inc. headquartered?
- Elicio Therapeutics, Inc. is headquartered in United States of America and employs approximately 32 people. It has been publicly traded since 2023.